Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic
activity of pembrolizumab plus chemotherapy when combined with various immunotherapy
induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).